CN115335050B - 用于治疗皮肤病症的化合物和组合物 - Google Patents
用于治疗皮肤病症的化合物和组合物 Download PDFInfo
- Publication number
- CN115335050B CN115335050B CN202180024047.XA CN202180024047A CN115335050B CN 115335050 B CN115335050 B CN 115335050B CN 202180024047 A CN202180024047 A CN 202180024047A CN 115335050 B CN115335050 B CN 115335050B
- Authority
- CN
- China
- Prior art keywords
- compound
- pyrrolidin
- yloxy
- trifluoromethyl
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410539437.6A CN118702672A (zh) | 2020-01-29 | 2021-01-28 | 用于治疗皮肤病症的化合物和组合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967500P | 2020-01-29 | 2020-01-29 | |
| US62/967,500 | 2020-01-29 | ||
| PCT/US2021/015449 WO2021154966A1 (en) | 2020-01-29 | 2021-01-28 | Compounds and compositions for use in treating skin disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410539437.6A Division CN118702672A (zh) | 2020-01-29 | 2021-01-28 | 用于治疗皮肤病症的化合物和组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115335050A CN115335050A (zh) | 2022-11-11 |
| CN115335050B true CN115335050B (zh) | 2024-05-17 |
Family
ID=77079457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180024047.XA Active CN115335050B (zh) | 2020-01-29 | 2021-01-28 | 用于治疗皮肤病症的化合物和组合物 |
| CN202410539437.6A Pending CN118702672A (zh) | 2020-01-29 | 2021-01-28 | 用于治疗皮肤病症的化合物和组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410539437.6A Pending CN118702672A (zh) | 2020-01-29 | 2021-01-28 | 用于治疗皮肤病症的化合物和组合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11807621B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4574822A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7785004B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102735703B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115335050B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021212754B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168103A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3032872T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE071972T2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL295088B2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL4096661T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154966A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4574822A3 (en) | 2020-01-29 | 2025-08-27 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| WO2023214375A1 (en) * | 2022-05-05 | 2023-11-09 | Kamari Pharma Ltd. | Methods of treating dermatological conditions and symptoms thereof |
| CN117164527B (zh) * | 2022-05-25 | 2026-02-17 | 大连理工大学 | 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法 |
| WO2024099404A1 (zh) | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | 一种含氮螺环类化合物、药物组合物以及其用途 |
| CN120202198A (zh) * | 2022-11-10 | 2025-06-24 | 北京普祺医药科技股份有限公司 | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 |
| CN117624036A (zh) * | 2023-10-30 | 2024-03-01 | 爱斯特(成都)生物制药股份有限公司 | 一种制备6-溴-3-氟-2-吡啶甲醛的方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001239694A1 (en) * | 2000-11-09 | 2002-07-25 | Accenture Global Services Limited | Method and system for managing inventory. |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| CN101287726A (zh) * | 2005-02-22 | 2008-10-15 | 诺瓦提斯公司 | 用作mglur5拮抗剂的吡咯烷和哌啶乙炔衍生物 |
| CN102307853A (zh) * | 2009-02-18 | 2012-01-04 | 弗·哈夫曼-拉罗切有限公司 | 作为nk3受体拮抗剂的吡咯烷衍生物 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| DE2961415D1 (en) | 1978-05-20 | 1982-01-28 | Bayer Ag | Heteroaryloxy-acetamides, process for their preparation and their use as herbicides |
| US4461896A (en) | 1979-02-07 | 1984-07-24 | Norwich Eaton Pharmaceuticals, Inc. | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids |
| DE3018075A1 (de) | 1980-05-10 | 1981-11-12 | Bayer Ag, 5090 Leverkusen | Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung |
| JPS56158702A (en) | 1980-05-12 | 1981-12-07 | Nippon Tokushu Noyaku Seizo Kk | Herbicide |
| US4273927A (en) | 1980-08-14 | 1981-06-16 | Morton-Norwich Products, Inc. | Converting enzyme inhibitor |
| DE3038652A1 (de) | 1980-10-13 | 1982-05-19 | Bayer Ag, 5090 Leverkusen | 5-chlor-benzoxazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| DE3038599A1 (de) | 1980-10-13 | 1982-05-19 | Bayer Ag, 5090 Leverkusen | Substituierte benzazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
| DE3418168A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | 6-chlorbenzazolyloxyacetamide |
| DE3422861A1 (de) | 1984-06-20 | 1986-01-02 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von heteroaryloxyacetamiden |
| US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
| US5196427A (en) | 1990-09-13 | 1993-03-23 | Eli Lilly And Company | 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| US5075313A (en) | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| DE4218433A1 (de) | 1992-06-04 | 1993-12-09 | Bayer Ag | Fluorbenzoxazolyloxyacetamide |
| DE4219246A1 (de) | 1992-06-12 | 1993-12-16 | Bayer Ag | Neue 2-(7-Chlor-2-benzoxazolyloxy)-acetamide |
| DE4230903A1 (de) | 1992-09-16 | 1994-03-17 | Bayer Ag | Fluorbenzthiazolyloxyacetamide |
| FR2707639B1 (fr) | 1993-06-30 | 1995-10-13 | Pf Medicament | Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B. |
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
| ES2184960T3 (es) | 1996-05-15 | 2003-04-16 | Pfizer | Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas. |
| BR9709085A (pt) | 1996-05-15 | 1999-08-03 | Pfizer | Novas 2,3-dissubstituído-4(3H)-quinazolinonas |
| US6380204B1 (en) | 1997-02-28 | 2002-04-30 | Pfizer Inc | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions |
| PT968194E (pt) | 1997-02-28 | 2004-08-31 | Pfizer Prod Inc | Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa |
| ATE229004T1 (de) | 1997-03-31 | 2002-12-15 | Korea Res Inst Chem Tech | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung |
| US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
| US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
| IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| JPH11279158A (ja) | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―4―オン誘導体の製造方法 |
| JP4327915B2 (ja) | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
| DE60017157T2 (de) | 1999-09-16 | 2005-12-22 | Curis, Inc., Cambridge | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
| US20030219806A1 (en) | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
| US20020156253A1 (en) | 2000-06-26 | 2002-10-24 | Curtis Rory A.J. | 48000 and 52920, novel human calcium channels and uses thereof |
| GB2372993A (en) | 2000-11-03 | 2002-09-11 | Smithkline Beecham Plc | Vanilloid Receptor 6 |
| IL155613A0 (en) | 2000-12-01 | 2003-11-23 | Bristol Myers Squibb Co | Novel human nucleic acid molecules and polypeptides emcoding a novel human ion channel expressed in spinal cord and brain |
| EP1399558A2 (en) | 2001-06-13 | 2004-03-24 | Novartis AG | Vanilloid receptor-related nucleic acids and polypeptides |
| WO2003043961A2 (en) | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
| US20040110777A1 (en) | 2001-12-03 | 2004-06-10 | Annis Gary David | Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests |
| US20040009537A1 (en) | 2002-01-11 | 2004-01-15 | Jack Roos | Methods of modulating and of identifying agents that modulate intracellular calcium |
| WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| US6649638B1 (en) | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| WO2004041755A2 (en) | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
| DE10330157A1 (de) | 2003-07-04 | 2005-02-03 | Zf Friedrichshafen Ag | Lastschaltgetriebe für Baumaschinen, insbesondere für Baggerlader und Telehandler |
| CA2531766C (en) | 2003-09-11 | 2012-11-27 | Tibotec Pharmaceuticals Ltd. | Entry inhibitors of the hiv virus |
| DE10351087A1 (de) | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
| EP1687306A1 (en) | 2003-11-14 | 2006-08-09 | MERCK SHARP & DOHME LTD. | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| AP2331A (en) | 2003-12-22 | 2011-12-05 | Pfizer | Triazole derivatives as vasopressin antagonists. |
| WO2005086895A2 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| US20050202539A1 (en) | 2004-03-11 | 2005-09-15 | Hydra Biosciences | System for screening eukaryotic membrane proteins |
| KR20070012407A (ko) | 2004-04-15 | 2007-01-25 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아미노피리미딘 유도체 |
| JP2008501707A (ja) | 2004-06-04 | 2008-01-24 | アイコス、コーポレーション | マスト細胞障害を処置するための方法 |
| KR101111099B1 (ko) | 2004-09-09 | 2012-02-17 | 아바야 테크놀러지 코퍼레이션 | 네트워크 트래픽 보안 방법들 및 시스템들 |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| US8916550B2 (en) | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| EP2392328A1 (en) | 2005-05-09 | 2011-12-07 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 Function |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| AU2006244027A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1) |
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US20100152209A1 (en) | 2005-11-04 | 2010-06-17 | Hydra Biosciences Inc. | Compounds for Modulating TRPV3 Function |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| KR101034300B1 (ko) | 2008-12-02 | 2011-05-16 | 고려대학교 산학협력단 | Trpv3 활성 억제 약물 및 이의 활용 |
| US8318928B2 (en) * | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
| EP2630138B1 (en) * | 2010-10-21 | 2015-06-03 | Bayer Intellectual Property GmbH | 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides |
| WO2012058132A1 (en) * | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| US20140018435A1 (en) | 2012-06-06 | 2014-01-16 | University Of Illinois Chicago | Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers |
| TWI710558B (zh) | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| US9617214B2 (en) * | 2013-11-08 | 2017-04-11 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| CA2932396C (en) * | 2013-12-03 | 2022-03-29 | Janssen Pharmaceutica Nv | Benzamide derivative useful as fasn inhibitors for the treatment of cancer |
| JP2017100948A (ja) | 2014-04-01 | 2017-06-08 | 大日本住友製薬株式会社 | 4−アリールイミダゾール誘導体 |
| EP3204379B1 (en) * | 2014-10-10 | 2019-03-06 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
| WO2016172631A2 (en) * | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| CN107417687A (zh) | 2016-05-24 | 2017-12-01 | 中国科学院上海药物研究所 | 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 |
| CN108570038B (zh) | 2017-03-08 | 2021-09-28 | 中国科学院上海药物研究所 | 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途 |
| EP4574822A3 (en) | 2020-01-29 | 2025-08-27 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| WO2023214375A1 (en) * | 2022-05-05 | 2023-11-09 | Kamari Pharma Ltd. | Methods of treating dermatological conditions and symptoms thereof |
-
2021
- 2021-01-28 EP EP25165470.3A patent/EP4574822A3/en active Pending
- 2021-01-28 EP EP21748179.5A patent/EP4096661B1/en active Active
- 2021-01-28 IL IL295088A patent/IL295088B2/en unknown
- 2021-01-28 CN CN202180024047.XA patent/CN115335050B/zh active Active
- 2021-01-28 KR KR1020227025104A patent/KR102735703B1/ko active Active
- 2021-01-28 CA CA3168103A patent/CA3168103A1/en active Pending
- 2021-01-28 ES ES21748179T patent/ES3032872T3/es active Active
- 2021-01-28 PL PL21748179.5T patent/PL4096661T3/pl unknown
- 2021-01-28 CN CN202410539437.6A patent/CN118702672A/zh active Pending
- 2021-01-28 US US17/160,802 patent/US11807621B2/en active Active
- 2021-01-28 AU AU2021212754A patent/AU2021212754B2/en active Active
- 2021-01-28 WO PCT/US2021/015449 patent/WO2021154966A1/en not_active Ceased
- 2021-01-28 HU HUE21748179A patent/HUE071972T2/hu unknown
- 2021-01-28 JP JP2022545405A patent/JP7785004B2/ja active Active
-
2023
- 2023-04-13 US US18/300,234 patent/US12435061B2/en active Active
-
2025
- 2025-09-04 JP JP2025146979A patent/JP2025175030A/ja active Pending
- 2025-10-19 IL IL324069A patent/IL324069A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001239694A1 (en) * | 2000-11-09 | 2002-07-25 | Accenture Global Services Limited | Method and system for managing inventory. |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| CN101287726A (zh) * | 2005-02-22 | 2008-10-15 | 诺瓦提斯公司 | 用作mglur5拮抗剂的吡咯烷和哌啶乙炔衍生物 |
| CN102307853A (zh) * | 2009-02-18 | 2012-01-04 | 弗·哈夫曼-拉罗切有限公司 | 作为nk3受体拮抗剂的吡咯烷衍生物 |
Non-Patent Citations (4)
| Title |
|---|
| 他扎罗汀的临床应用进展;陈晓莉;方红;;国外医学(老年医学分册);20060928(05);全文 * |
| 儿童特应性皮炎诊断和管理;汤建萍;;中国实用儿科杂志;20150106(01);全文 * |
| 温度敏感型瞬时受体电位通道与皮肤神经源炎症和瘙痒;谢志强;;浙江大学学报(医学版)(04);全文 * |
| 谢志强 ; .温度敏感型瞬时受体电位通道与皮肤神经源炎症和瘙痒.浙江大学学报(医学版).2009,(04),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240124413A1 (en) | 2024-04-18 |
| EP4096661C0 (en) | 2025-04-02 |
| US12435061B2 (en) | 2025-10-07 |
| CA3168103A1 (en) | 2021-08-05 |
| JP2023512664A (ja) | 2023-03-28 |
| WO2021154966A1 (en) | 2021-08-05 |
| EP4096661B1 (en) | 2025-04-02 |
| EP4096661A1 (en) | 2022-12-07 |
| IL295088A (en) | 2022-09-01 |
| CN118702672A (zh) | 2024-09-27 |
| EP4574822A2 (en) | 2025-06-25 |
| ES3032872T3 (en) | 2025-07-28 |
| KR102735703B1 (ko) | 2024-11-28 |
| EP4574822A3 (en) | 2025-08-27 |
| AU2021212754A1 (en) | 2022-08-04 |
| IL295088B2 (en) | 2026-04-01 |
| EP4096661A4 (en) | 2024-03-06 |
| KR20220139299A (ko) | 2022-10-14 |
| US20220332697A1 (en) | 2022-10-20 |
| JP7785004B2 (ja) | 2025-12-12 |
| US11807621B2 (en) | 2023-11-07 |
| HUE071972T2 (hu) | 2025-10-28 |
| NZ790364A (en) | 2025-12-19 |
| IL324069A (en) | 2025-12-01 |
| AU2021212754B2 (en) | 2026-05-21 |
| PL4096661T3 (pl) | 2025-09-01 |
| IL295088B1 (en) | 2025-12-01 |
| CN115335050A (zh) | 2022-11-11 |
| BR112022014933A2 (pt) | 2022-09-20 |
| JP2025175030A (ja) | 2025-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12435061B2 (en) | Compounds and compositions for use in treating skin disorders | |
| CN110300589B (zh) | 作为cftr增效剂的双环异杂芳基衍生物 | |
| CN105263326B (zh) | 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物 | |
| US11319317B2 (en) | (Hetero)arylamide compound for inhibiting protein kinase activity | |
| AU2015339196A1 (en) | Substituted tetrahydropyrans and method of use | |
| EP3596084A1 (en) | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof | |
| WO2019154252A1 (zh) | 取代的烟酰胺类化合物及药物组合物及其用途 | |
| US11091462B2 (en) | (Hetero)arylamide compound for inhibiting protein kinase activity | |
| CN102083817A (zh) | 作为itpkb抑制剂的化合物和组合物 | |
| TW201249825A (en) | Novel compounds | |
| HK40082455A (en) | Compounds and compositions for use in treating skin disorders | |
| BR122024002638B1 (pt) | Compostos e usos destes | |
| BR122024002638A2 (pt) | Compostos, composições compreendendo os mesmos, e usos destes | |
| HK40082455B (en) | Compounds and compositions for use in treating skin disorders | |
| BR112022014933B1 (pt) | Compostos ou sal farmaceuticamente aceitável dos mesmos e usos dos mesmos | |
| TW201946926A (zh) | 1-咪唑并噻二唑-2h-吡咯-5-酮衍生物 | |
| CN120530120A (zh) | 可用作mk2激酶的降解剂的化合物和组合物 | |
| CN117651698A (zh) | 吡啶酮mk2抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40082455 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |